Prenetics IM8 revenue jumps 359% in Q2, raises FY2026 guidance

Prenetics Global Limited (NASDAQ: PRE) reported second quarter fiscal 2026 financial results, with total revenue of $46.5 million, up approximately 288% year-over-year, according to a company statement dated August 18, 2026.

Revenue from its IM8 wellness brand reached $45.0 million for the quarter, up approximately 359% year-over-year, marking what the company described as its sixth consecutive record quarter. Both figures fell within the company's previously issued guidance ranges of $46–$48 million for total revenue and $44–$46 million for IM8 revenue.

The company said July was its strongest month on record for IM8, generating $20.9 million in revenue, representing an annualized run-rate of approximately $251 million.

Prenetics raised its full-year 2026 IM8 revenue guidance to $220–$230 million and initiated fiscal year 2027 IM8 revenue guidance of $400 million or more. The company also said July was the first month in which consolidated Adjusted Free Cash Flow turned positive, and that it expects the metric to remain positive through the third quarter and beyond. Adjusted Free Cash Flow is a non-IFRS measure defined as net cash from operating activities plus net fundings under the General Catalyst Customer Value Fund facility.

Danny Yeung, Chief Executive Officer of Prenetics and co-founder of IM8, said: "Twenty months ago, IM8 did not exist. This quarter it carried Prenetics to a sixth consecutive record, July became the biggest month in our history, and consolidated Adjusted Free Cash Flow turned positive for the first time and we expect it to remain positive from here."

The financial information presented is unaudited. Prior period figures have been re-presented under IFRS 5 following the divestiture of non-core businesses including ACT Genomics, Europa, and Insighta.

You May Also Be Interested In

• First Hydrogen signs deal to acquire 60% stake in robotics IP firm
• JPMorgan Downgrades AVI Limited (AVI:SJ) to Neutral
• Chime Financial (CHYM) PT Raised to $40 at Morgan Stanley